This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Heart Disease Hypertension Pulmonary 
HCPLive
JANUARY 31, 2025
Panelists discuss how the coexistence of heart disease and chronic obstructive pulmonary disease (COPD) requires careful management as these conditions significantly impact each other. In stable COPD, cardiovascular complications are a leading cause of mortality, whereas acute exacerbations can worsen heart function.
Science Daily - Heart Disease
AUGUST 21, 2024
A new study has found that asporin, a protein encoded by the ASPN gene, plays a protective role in pulmonary arterial hypertension (PAH).
119 
Frontiers in Cardiovascular Medicine
FEBRUARY 12, 2025
BackgroundCurrent evidence suggests that cardiovascular disease (CVD) plays a role in the progression of chronic obstructive pulmonary disease (COPD). However, the relationship between CVD and the severity of COPD remains inadequately understood.
52 
Science Daily - Heart Disease
DECEMBER 13, 2023
Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a new study.
115 
Heart BMJ
AUGUST 26, 2024
LEARNING OBJECTIVES Review the diagnostic pathway for pulmonary arterial hypertension (PAH) in congenital heart disease (CHD). Understand and interpret right heart catheterisation data in pulmonary hypertension related to CHD. Recognise the typical presentation of PAH in patients with CHD.
Journal of Cardiothoracic Surgery
APRIL 10, 2025
This study aims to assess the prognostic significance of non-invasive right ventricle-pulmonary artery coupling in patients with pulmonary hypertension associated with left heart disease (PH-LHD) and identify.
52 
Frontiers in Cardiovascular Medicine
FEBRUARY 13, 2025
Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed.
Frontiers in Cardiovascular Medicine
MAY 8, 2024
Patients with pulmonary hypertension associated with a left-right shunt include a wide spectrum of pathophysiological substrates, ranging from those characterized by pulmonary over-circulation to those with advanced pulmonary vascular disease.
Heart BMJ
MARCH 13, 2025
Historically viewed as a secondary consequence of left-sided heart disease or pulmonary hypertension, its pathophysiology and prognostic implications have garnered attention in recent years. 2 3 Furthermore, persistent.
52 
American College of Cardiology
FEBRUARY 25, 2025
William Boden and Bradley Maron discuss the latest advancements in managing pulmonary hypertension caused by left heart disease. In this interview, Drs.
Journal of Cardiothoracic Surgery
JUNE 26, 2024
Pulmonary arteriovenous fistula (PAVF) is a rare disease, and its symptoms lack specificity. For patients with coronary heart disease(CHD), hypertension and other common cardiovascular diseases, PAVF is easy t.
Frontiers in Cardiovascular Medicine
FEBRUARY 2, 2024
Aims A proportion of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) do not fit in the current classification.
Heart BMJ
FEBRUARY 12, 2024
Pulmonary arterial hypertension related to congenital heart disease as a paradigm of complexity Pulmonary arterial hypertension related to congenital heart disease (PAH-CHD) really represents a paradigm of complexity.
Science Daily - Heart Disease
JANUARY 22, 2025
A new molecular imaging technique -- 18F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression.
52 
Journal of the American Heart Association
SEPTEMBER 12, 2024
Due to improvements in recognition and management of their multisystem disease, the long‐term survival of infants, children, and adolescents with trisomy 21 and congenital heart disease now matches children with congenital heart disease and no genetic condition in many scenarios.
Journal of the American Heart Association
NOVEMBER 28, 2023
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundPulmonary artery hypertension (PAH) is a fatal disease characterized by a complex pathogenesis. Transpulmonary exosomal miRs offer valuable insights into pulmonary circulation microenvironments.
Heart BMJ
FEBRUARY 12, 2024
Objective This study assessed the long-term effects of triple therapy with prostanoids on patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as there is limited information on the safety and efficacy of this treatment approach.
DAIC
JUNE 4, 2024
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Scientists Suggest a New Method for Diagnosing Heart Diseases 6. Weight Loss Drug Linked with Reduced Need for Diuretics in Heart Failure Patients 7. Tenax Therapeutics Announces New U.S.
Open Heart
JUNE 6, 2023
Objective Pulmonary hypertension (PHT) commonly coexists with significant mitral regurgitation (MR), but its prevalence and prognostic importance have not been well characterised. In a large cohort of adults with moderate or greater MR, we aimed to describe the prevalence and severity of PHT and assess its influence on outcomes.
Journal of the American Heart Association
NOVEMBER 28, 2023
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundLeft heart disease is the most common cause of pulmonary hypertension (PH) and is frequently accompanied by increases in pulmonary vascular resistance.
40 
Frontiers in Cardiovascular Medicine
JANUARY 11, 2024
Objective Early risk assessment of pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is crucial to ensure timely treatment. Class Activation Mapping (CAM) images demonstrated the model's attention focused on the pulmonary artery segment.
59 
Frontiers in Cardiovascular Medicine
MAY 8, 2024
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that eventually leads to heart failure (HF) and subsequent fatality if left untreated. Right ventricular (RV) function has proven prognostic values in patients with a variety of heart diseases including PAH.
40 
Science Daily - Heart Disease
APRIL 11, 2024
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.
All About Cardiovascular System and Disorders
FEBRUARY 14, 2024
Crochetage sign on ECG in ASD ECG in ASD with severe pulmonary hypertension: Tall R’ in V1, ST depression in inferior leads and V2-V5, and T inversion in inferior leads and V1-V6 are seen. All these features together in a cyanotic congenital heart disease is characteristic of tricuspid atresia.
The American Journal of Cardiology
SEPTEMBER 3, 2024
Publication date: Available online 2 September 2024 Source: The American Journal of Cardiology Author(s): Alexandra C. van Dissel, Michele D'Alto, Andrea Farro, Harold Mathijssen, Marco C. Post, Pier P. Bassareo, Arie P.J. van Dijk, Barbara J.M. Mulder, Berto J.
Frontiers in Cardiovascular Medicine
FEBRUARY 14, 2024
Specifically, this genetic factor was found to lower the risk of type 2 diabetes by 46.5%, coronary heart disease by 37.5%, ischemic stroke by 35.4%, cardiac-related mortality by 28.6%, heart failure by 28.2%, transient ischemic attack by 24%, atrial fibrillation by 15.2%, peripheral artery disease by 0.3%, and hypertension by 0.3%.
49 
All About Cardiovascular System and Disorders
JANUARY 14, 2024
Right Heart Catheterization in Tetralogy of Fallot With the availability of high resolution echocardiographic images and Doppler echocardiography, role of cardiac catheterization has come down in tetralogy of Fallot and other congenital heart diseases in general. Normal subjects have a value around 2.1.
CardiacWire
JANUARY 24, 2024
Expanding access to heart disease detection is one of cardiology’s biggest challenges, and Finnish startup CardioSignal just raised $10M to address that challenge using one of the most accessible devices in the world – the smartphone.
75 
Open Heart
JUNE 1, 2022
Objectives To compare the shape and strength of the associations of resting heart rate (RHR) with incident heart failure (HF) and pulmonary heart disease (PHD) in Chinese adults. Cox regression yielded HRs for each disease associated with usual RHR after adjustment for confounding factors.
Ken Grauer, MD
MARCH 27, 2024
Statistically — When an older adult with known underlying heart disease presents to the ED in a regular WCT rhythm, but without clear sign of sinus P waves — the odds that the rhythm will turn out to be VT are ~90% even before you look at the ECG. PEARL # 2: How Might the History Help?
186 
BoardVitals - Cardiovascular
JUNE 14, 2017
In preparation for the ABIM Cardiovascular Disease exam, check out the BoardVitals Cardiology Board Review Question Bank and we’ll make sure you’re well versed in the following 13 areas covered on the exam: Multiple-Choice Component Arrhythmias 15% Coronary Artery Disease 23% Heart Failure and Cardiomyopathy 17% Valvular Disease 15% Pericardial (..)
BoardVitals - Cardiovascular
JULY 26, 2022
The exam covers the following topics: Arrhythmias 15% Coronary Artery Disease 21.5% Heart Failure and Cardiomyopathy 19% Valvular Disease 15% Pericardial Disease 3% Congenital Heart Disease 3% Vascular Diseases 5% Systemic Hypertension and Hypotension 8.5%
Dr. S. Venkatesan MD
APRIL 18, 2024
Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heart disease, whether it is valvular or myocardial disease. This is to create a small regulatory orifice in the IAS ( A complicated term for a small ASD ) to decompress the LA and reduce pulmonary congestive symptoms.
BoardVitals - Cardiovascular
MAY 15, 2022
The Cardiology MOC exam covers the following subjects : Arrhythmias 15% Coronary Artery Disease 21.5% Heart Failure and Cardiomyopathy 19% Valvular Disease 15% Pericardial Disease 3% Congenital Heart Disease 3% Vascular Diseases 5% Systemic Hypertension and Hypotension 8.5%
Ken Grauer, MD
SEPTEMBER 15, 2024
consistent with RAA (which is consistent with this patient’s underlying heart disease. Perhaps the patient has pulmonary hypertension and/or tricuspid regurgitation? RED arrows show what looks to be sinus P waves that are HUGE !!!! In the meantime, a pacemaker may be needed. =
78 
Ken Grauer, MD
APRIL 13, 2024
PEARL # 1: Given a potentially longterm course for the patient with an ASD — it's important to appreciate that a lack of symptoms does not necessarily exclude the possibility of hemodynamically significant heart disease.
116 
All About Cardiovascular System and Disorders
MARCH 30, 2024
Transcript of the video: Ebstein’s Anomaly is one of the cyanotic congenital heart disease in which survival to adult life is common. The cyanosis in Ebstein’s anomaly, is usually not due to pulmonary hypertension, but because tricuspid regurgitation jet is directed across the atrial septal defect.
52 
All About Cardiovascular System and Disorders
MARCH 20, 2024
Right atrial hypertrophy as in tricuspid stenosis, pulmonary stenosis and pulmonary hypertension. But in a VSD with pulmonary hypertension A wave is not prominent. So a prominent A wave in a complex congenital heart disease situation would indicate that interventricular septum is intact.
52 
Dr. Smith's ECG Blog
NOVEMBER 19, 2016
It was edited by Smith CASE : A 52-year-old male with a past medical history of hypertension and COPD summoned EMS with complaints of chest pain, weakness and nausea. The patient was transported to the CCU for further medical optimization where a pulmonary artery catheter was placed. The mean MAP for these patients was 81 +/- 13.
40 
Science Daily - Heart Disease
MAY 2, 2024
This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic lung disease, heart failure and death.
122 
Open Heart
DECEMBER 14, 2023
Objective To determine the magnitude of any excess risk of mortality and hospitalisation due to COVID-19 infection in patients with congenital heart disease (CHD) in the UK healthcare system. Of patients with a positive COVID-19 test, patients with CHD were more likely than controls to be hospitalised (22.4%
98 
MIBHS
OCTOBER 31, 2024
There are numerous factors that can lead to cardiomegaly, ranging from temporary conditions to chronic diseases. High Blood Pressure (Hypertension) Persistent high blood pressure forces the heart to work harder to pump blood. Over time, this additional strain causes the heart muscle to thicken, enlarging the heart.
Heart 2023 Conference
APRIL 20, 2022
Stroke) A Danish study indicated that combining nitrates and PDE5 inhibitors isn't always a terrible idea for men with ischemic heart disease and erectile dysfunction. JACC: Asia) Lexaria Bioscience has announced that a CBD product beats a placebo in simulating acute pulmonary hypertension.
52 
Frontiers in Cardiovascular Medicine
JANUARY 14, 2024
Its use has been approved in the adult population with heart failure and described for pulmonary hypertension (PH). Only case reports and small series have been published about its use in the paediatric population and for congenital heart disease (CHD).
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content